Economic consequences of molecular profiling for metastatic solid tumors. Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) ...

Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings. Objectives: ...

Temporary COVID-19 guideline recommendations have recently been issued to expand the use of colony-stimulating factors in patients with cancer with intermediate to high risk for febrile neutropenia ...

Gary Lyman, MD, MPH, an oncologist and hematologist, compares the uptake of filgrastim biosimlars with pegfilgrastim biosimilars. Gary Lyman, MD, MPH, is an oncologist, hematologist, and public health ...

DUBLIN, Jan. 18, 2021 /PRNewswire/ -- The "Filgrastim Biosimilars Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth" report has been added to ...

The FDA approval of Fylnetra, a biosimilar for Neulasta, has the potential to offer patients with cancer a neutropenia treatment option at a lower cost. The Food and Drug Administration (FDA) approved ...

The global pharmaceutical industry is witnessing a significant evolution, driven by advancements in biotechnology and increasing healthcare needs. One notable segment within this industry is the ...